.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, people with metastatic gastrointestinal tumors that acquired biomarker-matched treatments based upon spreading cyst DNA profiling presented a better medical advantage than those getting unmatched therapy.